Yetian Dong
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: July 23, 2026
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Bone marrow transplantation
Published: April 12, 2025
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result.
Journal: Journal of advanced research
Published: November 16, 2024
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Journal: Experimental hematology & oncology
Published: October 16, 2024
Outcome of Pneumocystis Jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies.
Journal: BMC infectious diseases
Published: June 20, 2024
The way of SARS-CoV-2 vaccine development: success and challenges.
Journal: Signal transduction and targeted therapy
Published: June 28, 2021
A systematic review of SARS-CoV-2 vaccine candidates.
Journal: Signal transduction and targeted therapy
Published: July 10, 2020
Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 21, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026